Gsa Capital Partners LLP Uro Gen Pharma Ltd. Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

A detailed history of Gsa Capital Partners LLP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 19,597 shares of URGN stock, worth $219,682. This represents 0.02% of its overall portfolio holdings.

Number of Shares

19,597

Holding current value

$219,682

% of portfolio

0.02%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	BUY	$12.7 - $17.92 $248,881 - $351,178	19,597 New	19,597 $249,000
Q1 2024 May 03, 2024	BUY	$13.81 - $19.33 $206,279 - $288,732	14,937 New	14,937 $224,000
Q3 2023 Nov 15, 2023	BUY	$8.84 - $22.64 $90,070 - $230,678	10,189 New	10,189 $142,000
Q4 2022 Feb 13, 2023	SELL	$7.55 - $11.96 $137,228 - $217,384	-18,176 Reduced 36.93%	31,046 $275,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $6,856 - $8,948	951 Added 1.97%	49,222 $410,000
Q2 2022 Aug 09, 2022	SELL	$5.12 - $8.74 $45,839 - $78,249	-8,953 Reduced 15.65%	48,271 $395,000
Q1 2022 May 11, 2022	BUY	$5.92 - $9.73 $107,507 - $176,696	18,160 Added 46.49%	57,224 $498,000
Q4 2021 Feb 14, 2022	BUY	$9.03 - $19.13 $167,587 - $355,033	18,559 Added 90.51%	39,064 $371,000
Q3 2021 Nov 12, 2021	SELL	$14.31 - $18.39 $105,579 - $135,681	-7,378 Reduced 26.46%	20,505 $345,000
Q2 2021 Aug 05, 2021	BUY	$15.2 - $20.94 $65,952 - $90,858	4,339 Added 18.43%	27,883 $426,000
Q1 2021 May 10, 2021	BUY	$17.99 - $26.96 $423,556 - $634,746	23,544 New	23,544 $459,000
Q1 2018 May 11, 2018	SELL	$38.64 - $57.54 $394,128 - $586,908	-10,200 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$27.28 - $43.26 $24,552 - $38,934	900 Added 9.68%	10,200 $380,000
Q3 2017 Nov 20, 2017	BUY	$17.15 - $32.72 $159,495 - $304,296	9,300	9,300 $293,000

Others Institutions Holding URGN

# of Institutions

127

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $255M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Uro Gen Pharma Ltd. Transaction History